ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2010
A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 288 citations in OpenAlex.
- Innovative aptamer approaches in glial tumor diagnostics and therapy: Progress and future directions.Molecular therapy. Nucleic acids · 2025Review
- Aptamer-Nanoconjugates as Potential Theranostics in Major Neuro-Oncological and Neurodegenerative Disorders.Pharmaceutics · 2025Review
- Emerging Applications of EpCAM-Targeted Nuclear Medicine Probes: Current Research and Future Perspectives.International journal of nanomedicine · 2025Review
- Cycloastragenol in inflammation-related diseases: mechanisms, pharmacokinetics, and translational prospects.Frontiers in pharmacology · 2025Review
- Review
- Modular Fabrication of Bioorthogonal Nanozymes for Biomedical Applications.Advanced materials (Deerfield Beach, Fla.) · 2024Review
- Aptamers in neuro-oncology: An emerging therapeutic modality.Neuro-oncology · 2024Review
- The Advancing Role of Nanocomposites in Cancer Diagnosis and Treatment.International journal of nanomedicine · 2024Review
- Breast cancer in young Indian women: factors, challenges in screening, and upcoming diagnostics.Journal of cancer research and clinical oncology · 2023Review
- Oncogene-targeting nanoprobes for early imaging detection of tumor.Journal of nanobiotechnology · 2023Review
- Aptamer-Based Probes for Cancer Diagnostics and Treatment.Life (Basel, Switzerland) · 2022Review
- Advances in aptamer-based nuclear imaging.European journal of nuclear medicine and molecular imaging · 2022Review
- Nanomaterial Probes for Nuclear Imaging.Nanomaterials (Basel, Switzerland) · 2022Review
- Metastatic and non-metastatic melanoma imaging using Sgc8-c aptamer PTK7-recognizer.Scientific reports · 2021Article
- Future Perspectives of Therapeutic, Diagnostic and Prognostic Aptamers in Eye Pathological Angiogenesis.Cells · 2021Review
- AS1411-functionalized delivery nanosystems for targeted cancer therapy.Exploration of medicine · 2021Article
- Overcoming Barriers for siRNA Therapeutics: From Bench to Bedside.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Selection of aptamers targeted to food-borne pathogenic bacteriaFood science & nutrition · 2020Article
- Aptamers Increase Biocompatibility and Reduce the Toxicity of Magnetic Nanoparticles Used in Biomedicine.Biomedicines · 2020Review
- Present Scenario of Bioconjugates in Cancer Therapy: A Review.International journal of molecular sciences · 2019Review
23 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledThe recent advances in molecular imaging techniques, using cancer-targeting nanoparticle probes, provide noninvasive tracking information on cancer cells in living subjects. Here, we report a multimodal cancer-targeted imaging system capable of concurrent fluorescence imaging, radionuclide imaging, and MRI in vivo.
methodsA cobalt-ferrite nanoparticle surrounded by fluorescent rhodamine (designated MF) within a silica shell matrix was synthesized with the AS1411 aptamer (MF-AS1411) that targets nucleolin (a cellular membrane protein highly expressed in cancer) using N-(3-dimethylaminopropyl)-N-ethylcarbodiimide (EDC). This purified MF-AS1411 particle was bound with 2-(p-isothio-cyanatobenzyl)-1,4,7-triazacyclonane-1,4,7-triacetic acid (p-SCN-bn-NOTA) chelating agent and further labeled with (67)Ga-citrate (MFR-AS1411). The shape and size distribution of MFR-AS1411 were characterized by transmission electron microscope (TEM). The cellular distribution of the nucleolin protein using the MFR-AS1411 nanoparticle was detected by fluorescence confocal microscopy. Phantom MR images were obtained as the concentration of MFR-AS1411 increased, using a 1.5-T MRI scanner. In vivo (67)Ga radionuclide imaging and MRI were performed using a gamma-camera and a 1.5-T MR imager, respectively.
resultsTEM imaging revealed MF and MFR-AS1411 to be spheric and well dispersed. The purified MFR-AS1411 nanoparticle showed specific fluorescence signals in nucleolin-expressing C6 cells, compared with MFR-AS1411 mutant (MFR-AS1411mt)-treated C6 cells. The rhodamine fluorescence intensity and (67)Ga activity of MFR-AS1411 were enhanced in a dose-dependent manner as the concentration of MFR-AS1411 was increased. The (67)Ga radionuclide was detected in both thighs of the mice injected with MFR-AS1411, whereas the MFR-AS1411 mutant (MFR-AS1411mt) administration revealed rapid clearance via the bloodstream, demonstrating that MFR-AS1411 specifically targeted cancer cells. Bioluminescence images in the C6 cells, stably expressing the luciferase gene, illustrated the in vivo distribution. T2-weighted MR images of the same mice injected with MFR-AS1411 showed dark T2 signals inside the tumor region, compared with the MRI signal of the tumor region injected with MFR-AS1411mt particles.
conclusionWe developed a nanoparticle-based cancer-specific imaging probe using the AS1411 aptamer in vivo and in vitro. This multimodal targeting imaging strategy, using a cancer-specific AS1411 aptamer, can be used as a versatile imaging tool for specific cancer diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.